Skip to content

Study · Not a test of the peptide alone · 2014

2 results

Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide.

Holm J, Eiken P, Hyldstrup L, Jensen JE

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Oct 2014Cited by 18 (Europe PMC)

PMID24936568 (opens in a new tab)DOI10.4158/ep14141.cr (opens in a new tab)PepBankPUB-24936568
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome

    In a patient with osteogenesis imperfecta, early fracture healing appeared after exchange fixation and initiation of teriparatide.

    In plain wordsIn a patient with osteogenesis imperfecta, an X-ray showed early fracture healing after repeat fixation and teriparatide initiation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEarly fracture healing
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    An X-ray 1 month later showed early signs of fracture healing.
    2 context sentences
    Summary · context
    This is a case report of an AFF treated with teriparatide.
    Summary · context
    Due to nonunion and another fracture distal to the nail, the patient was reoperated on with exchange ORIF and off-label treatment with teriparatide 20 μg/day was started.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome

    In a patient with osteogenesis imperfecta receiving teriparatide after exchange fixation, both right femoral fractures showed solid healing.

    In plain wordsIn a patient with osteogenesis imperfecta receiving teriparatide after repeat fixation, both right femoral fractures healed solidly.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSolid healing of both femoral fractures
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    A subsequent X-ray 6 months after the last operation showed a solid healing of both right femoral fractures.
    2 context sentences
    Summary · context
    This is a case report of an AFF treated with teriparatide.
    Summary · context
    Due to nonunion and another fracture distal to the nail, the patient was reoperated on with exchange ORIF and off-label treatment with teriparatide 20 μg/day was started.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.